JP2016509222A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509222A5
JP2016509222A5 JP2015556042A JP2015556042A JP2016509222A5 JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5 JP 2015556042 A JP2015556042 A JP 2015556042A JP 2015556042 A JP2015556042 A JP 2015556042A JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5
Authority
JP
Japan
Prior art keywords
acid
subject
biomarkers
level
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015556042A
Other languages
English (en)
Japanese (ja)
Other versions
JP6404834B2 (ja
JP2016509222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011759 external-priority patent/WO2014120449A1/en
Publication of JP2016509222A publication Critical patent/JP2016509222A/ja
Publication of JP2016509222A5 publication Critical patent/JP2016509222A5/ja
Application granted granted Critical
Publication of JP6404834B2 publication Critical patent/JP6404834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015556042A 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 Active JP6404834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361758924P 2013-01-31 2013-01-31
US61/758,924 2013-01-31
PCT/US2014/011759 WO2014120449A1 (en) 2013-01-31 2014-01-16 Biomarkers related to insulin resistance progression and methods using the same

Publications (3)

Publication Number Publication Date
JP2016509222A JP2016509222A (ja) 2016-03-24
JP2016509222A5 true JP2016509222A5 (enExample) 2017-02-09
JP6404834B2 JP6404834B2 (ja) 2018-10-17

Family

ID=51262841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556042A Active JP6404834B2 (ja) 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法

Country Status (5)

Country Link
US (2) US9910047B2 (enExample)
EP (2) EP3321686B1 (enExample)
JP (1) JP6404834B2 (enExample)
ES (2) ES2987582T3 (enExample)
WO (1) WO2014120449A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6367915B2 (ja) * 2013-03-28 2018-08-01 ネステク ソシエテ アノニム 体重増加予防のためのプレバイオティクス効力のバイオマーカーとしてのインドキシル硫酸
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
SG11201810254UA (en) * 2016-05-17 2018-12-28 Univ Osaka Blood sample analysis method and system, for determining diabetes
WO2017210097A1 (en) 2016-06-02 2017-12-07 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
EP3555615B9 (en) * 2016-12-19 2025-03-19 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of kidney function metabolites
WO2018150077A1 (en) * 2017-02-16 2018-08-23 Afekta Technologies Oy Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases
JP7337701B2 (ja) * 2017-03-31 2023-09-04 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー インスリン及びｃ－ペプチドの定量の方法
EP3401683A1 (en) * 2017-05-10 2018-11-14 Eberhard Karls Universität Tübingen Medizinische Fakultät Diagnosing metabolic disease by the use of a biomarker
CN111727038B (zh) * 2018-01-17 2025-05-13 南安普顿大学 肌肉减少症和nad缺乏的风险预测及分级方法
EP3857232A1 (en) * 2018-09-27 2021-08-04 Société des Produits Nestlé S.A. Markers of risk to develop insulin resistance during childhood and young adulthood
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
KR102231928B1 (ko) * 2019-09-19 2021-03-26 고려대학교 산학협력단 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물
CA3177108A1 (en) * 2020-04-27 2021-11-04 Wayne R. Matson Detection and modification of gut microbial population
CN112149311B (zh) * 2020-10-12 2021-10-26 北京中恒利华石油技术研究所 一种基于数量规约的非线性多元统计回归测井曲线预测方法
CN112843036A (zh) * 2021-01-29 2021-05-28 中国药科大学 β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用
CN114113573B (zh) * 2021-11-08 2022-11-11 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病(cvd)的生物标志物及其用途
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
WO2023194615A1 (en) * 2022-04-07 2023-10-12 Need4Health B.V. Method for determining insulin dosage
JP7736971B2 (ja) * 2022-10-18 2025-09-10 株式会社オルトメディコ 糖尿病境界域者のスクリーニング方法
WO2024097429A1 (en) * 2022-11-05 2024-05-10 Texas Tech University System Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20020009740A1 (en) 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
JP4717810B2 (ja) 2003-06-20 2011-07-06 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド １型糖尿病と２型糖尿病を識別するためのバイオマーカー
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP2369346B1 (en) * 2006-03-24 2014-08-27 Metanomics GmbH Method for diagnosing diabetes type II
CA2690541A1 (en) * 2007-07-17 2009-01-29 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
US20110311650A1 (en) * 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
WO2010007106A1 (en) * 2008-07-15 2010-01-21 Metanomics Health Gmbh Means and methods diagnosing gastric bypass and conditions related thereto
EP2414535A4 (en) * 2009-03-31 2012-12-26 Metabolon Inc BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHOD OF USE THEREOF
US8367418B2 (en) 2009-10-23 2013-02-05 Therasyn Sensors, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20140303228A1 (en) * 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
AU2012335781A1 (en) * 2011-11-11 2014-05-29 Metabolon, Inc. Biomarkers for bladder cancer and methods using the same
JP2015505965A (ja) * 2011-12-09 2015-02-26 メタボロン，インコーポレイテッド 腎癌のバイオマーカーおよびそれを用いる方法

Similar Documents

Publication Publication Date Title
JP2016509222A5 (enExample)
Vaes et al. Changes in physical activity and all-cause mortality in COPD
Kim et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea
Jentsch et al. Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses
ter Horst et al. Methods for quantifying adipose tissue insulin resistance in overweight/obese humans
Henderson et al. How are physical activity, fitness, and sedentary behavior associated with insulin sensitivity in children?
ES2669620T3 (es) Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan
JP2016520192A5 (enExample)
Durrer et al. Differential impact of acute high-intensity exercise on circulating endothelial microparticles and insulin resistance between overweight/obese males and females
Reijnierse et al. The association between parameters of malnutrition and diagnostic measures of sarcopenia in geriatric outpatients
Roumen et al. Predictors of lifestyle intervention outcome and dropout: the SLIM study
JP2018502286A5 (enExample)
Pietrobelli et al. Adipose tissue and metabolic effects: new insight into measurements
García-Hermoso et al. Fatness mediates the influence of muscular fitness on metabolic syndrome in Colombian collegiate students
Zagatto et al. Relationship between anaerobic capacity estimated using a single effort and 30-s tethered running outcomes
Aerenhouts et al. Estimating body composition in adolescent sprint athletes: Comparison of different methods in a 3 years longitudinal design
Ning et al. Serum creatinine-and cystatin C-based indices are associated with the risk of subsequent sarcopenia: evidence from the China health and retirement longitudinal study
Jayasinghe et al. Fitter women did not have attenuated hemodynamic responses to psychological stress compared with age-matched women with lower levels of fitness
Golec et al. Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study
Boghosian et al. Risk factors for developing Perthes disease: a comprehensive national analysis spanning 2 decades
Espinosa-Flores et al. A scoping review of the methods used in patients with liver cirrhosis to assess body composition and their nutritional findings
Tee et al. Effects of exercise modality combined with moderate hypoxia on blood glucose regulation in adults with overweight
Zuniga et al. The effect of different exercise protocols and regression-based algorithms on the assessment of the anaerobic threshold
Vollrath et al. Acute Adrenal Suppression Following Resistance Training in Elite Female Athletes: A Comprehensive Steroid Profile
Dunican Seeing the forest for the trees: fractal dimensions measure COPD airway remodeling